The submission is based on the results of two phase Ib/II studies that evaluated Venclexta in combination with azacitidine or decitabine or with LDAC in this patient population.
Data from the phase Ib M14-358 study showed Venclexta in combination with azacitidine or decitabine resulted in a complete response/complete remission with incomplete hematologic recovery (CR/CRi) of 73% in patients treated with Venclexta at a dose of 400 mg.
The observed median overall survival (OS) across all Venclexta dose groups in the study was 17.5 months.
Results from the phase Ib/II M14-387 study of Venclexta in combination with LDAC showed a CR/CRi rate of 62% in patients treated with Venclexta at a dose of 600 mg. The observed median OS was 11.4 months.
Venclexta is a small molecule designed to selectively bind and inhibit the BCL-2 protein, which plays an important role in apoptosis.
Overexpression of the BCL-2 protein in AML has been associated with resistance to certain therapies.
It is believed that blocking BCL-2 may restore the signaling system that tells cells, including cancer cells, to self-destruct.
Genentech discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval